Pfizer suspends tanezumab osteoarthritis clinical programme

Thursday 24 June 2010

At the request of the US Food and Drug Administration, Pfizer Inc has suspended the clinical development programme for its investigational compound for osteoarthritis, tanezumab. The clinical hold follows reports of adverse events.

Full text available to subscribers only. Click here for information on subscribing to MedNous.